A real-world study of 219 adults with suspected IBS found that patients who underwent IBS-Smart and/or Trio-Smart testing had lower rates of colonoscopy and upper endoscopy than those who received neither test. The biggest difference was seen in patients who received both tests, with colonoscopy performed in 27.3% vs. 60.7% of the untested group.
The tested groups also had substantially lower observed diagnostic and gastroenterology office-visit costs, averaging $360–$385 per patient per month vs. $960 among untested patients. The authors suggest that targeted noninvasive testing could help streamline the IBS diagnostic workup and reduce downstream testing, while emphasizing that the findings are observational and require prospective validation.